INBX — Inhibrx Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $175.88m
- $23.29m
- $0.20m
- 52
- 80
- 58
- 68
Annual cashflow statement for Inhibrx Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -76.1 | -81.8 | -145 | -241 | 1,688 |
| Depreciation | |||||
| Non-Cash Items | 14.4 | 17.8 | 25.5 | 31.5 | -1,936 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 12.7 | -17.5 | 3.16 | 15.3 | 52.1 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -48 | -80.3 | -115 | -193 | -194 |
| Capital Expenditures | -1.36 | -0.864 | -0.686 | -4.59 | -2.6 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | 0.055 | 0 | — | — |
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -1.36 | -0.809 | -0.686 | -4.59 | -2.6 |
| Financing Cash Flow Items | -11.8 | -0.382 | -0.44 | -0.355 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 166 | 83.8 | 259 | 202 | 71.7 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 117 | 2.64 | 143 | 4.06 | -125 |